DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal

Dow Jones04-30 06:12

By Kelly Cloonan

DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista Therapeutics as KalVista plots a potential sale.

DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday.

DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal.

The company said it hasn't determined any actions it may take regarding the deal.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

April 29, 2026 18:12 ET (22:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2631422527?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 06:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631422527","market":"nz","top_or_hot":-1,"title":"DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> as KalVista plots a potential sale. \n</p>\n<p>\n  DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday. \n</p>\n<p>\n  DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal. \n</p>\n<p>\n  The company said it hasn't determined any actions it may take regarding the deal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 18:12 ET (22:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-30 06:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> as KalVista plots a potential sale. \n</p>\n<p>\n  DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday. \n</p>\n<p>\n  DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal. \n</p>\n<p>\n  The company said it hasn't determined any actions it may take regarding the deal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 18:12 ET (22:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631422527","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631422527","pubTimestamp":1777500720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista Therapeutics as KalVista plots a potential sale.DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday.DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal.The company said it hasn't determined any actions it may take regarding the deal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4581":"高盛持仓","DRI":"达登饭店","BK4504":"桥水持仓","XLV":"健康照护类股ETF-SPDR","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","XBI":"SPDR S&P Biotech ETF","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","BK4209":"餐馆","BK4137":"综合支持服务","BK4588":"碎股","HCSG":"Healthcare Svcs Group Inc","BK4585":"ETF&股票定投概念","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技"},"translate_title":"DRI Healthcare Trust在Chiesi交易提案后评估与KalVista的特许权使用费协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9,"XBI":0.6,"XLV":1.5,"HCSG":1.5,"LABU":0.6,"DRI":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista Therapeutics as KalVista plots a potential sale. \n\n\n  DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday. \n\n\n  DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal. \n\n\n  The company said it hasn't determined any actions it may take regarding the deal. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 18:12 ET (22:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631422527","isCrawlerRequest":true}